Emma Hudson
A5101721812- Endometrial and Cervical Cancer Treatments
- Hepatitis C virus research
- Ovarian cancer diagnosis and treatment
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cervical Cancer and HPV Research
- Pancreatic function and diabetes
- Metabolism, Diabetes, and Cancer
- PARP inhibition in cancer therapy
- Angiogenesis and VEGF in Cancer
- Metastasis and carcinoma case studies
- Lung Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Systemic Lupus Erythematosus Research
- Urinary and Genital Oncology Studies
- Estrogen and related hormone effects
- Cancer, Hypoxia, and Metabolism
- Cancer Risks and Factors
- Gastric Cancer Management and Outcomes
- Sarcoma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Lung Cancer Research Studies
- Calcium signaling and nucleotide metabolism
Velindre NHS Trust
2006-2025
Velindre Cancer Centre
2013-2025
Michigan Medicine
2024
Oxford BioMedica (United Kingdom)
2018-2024
Open Data Institute
2024
John Radcliffe Hospital
2024
University of Dundee
2002-2024
National Health Service Wales
2023-2024
Medawar Building for Pathogen Research
2016-2023
University of Oxford
2016-2021
Abstract Mucosal-associated invariant T (MAIT) cells are abundant in humans and recognize bacterial ligands. Here, we demonstrate that MAIT also activated during human viral infections vivo . activation was observed infection with dengue virus, hepatitis C virus influenza virus. This activation—driving cytokine release Granzyme B upregulation—is TCR-independent but dependent on IL-18 synergy IL-12, IL-15 and/or interferon-α/β. levels cell correlate disease severity acute infection....
In the rat liver epithelial cell line Clone 9, Vmax for glucose uptake is actuely increased by inhibition of oxidative phosphorylation and osmotic stress. By using a membrane-impermeant photoaffinity labelling reagent together with an isoform-specific antibody, we have, first time, provided direct evidence involvement GLUT1 transporter isoform in this response. Transport stimulation was found to be associated enhanced accessibility its substrate photolabelling formerly `cryptic' exofacial...
Hepatitis C virus (HCV) is a highly variable pathogen that frequently establishes chronic infection. This genetic variability affected by the adaptive immune response but contribution of other host factors unclear. Here, we examined role played interferon lambda-4 (IFN-λ4) on HCV diversity; IFN-λ4 plays crucial in spontaneous clearance or establishment chronicity following acute We performed viral genome-wide association studies using human and data from 485 patients white ancestry infected...
ABSTRACT Affordable next-generation sequencing (NGS) technologies for hepatitis C virus (HCV) may potentially identify both viral genotype and resistance genetic motifs in the era of directly acting antiviral (DAA) therapies. This study compared ability high-throughput NGS methods to generate full-length, deep, HCV sequence data sets evaluated their utility diagnostics clinical assessment. using (i) unselected RNA (metagenomics), (ii) preenrichment by probe capture, (iii) preamplification...
Background: Adrenal-protocol CT is commonly performed to distinguish adrenal adenomas from other tumors. However, the technique's utility among heterogeneous nodules not well established, and optimal method for placing ROIs in clearly defined.
Abstract Sustained viral response (SVR) rates for direct‐acting antiviral (DAA) therapy hepatitis C virus (HCV) infection routinely exceed 95%. However, a small number of patients require retreatment. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is potent DAA combination primarily used the retreatment who failed by therapies. Here we evaluate outcomes effects resistance‐associated substitutions (RAS) in real‐world cohort, including large genotype (GT)3 infected patients. 144 from...
TPS5623 Background: Carboplatin-paclitaxel chemotherapy (with trastuzumab for HER2+ uterine serous carcinoma) is the standard of care first-line systemic treatment recurrent or metastatic endometrial carcinoma (EC), which has a 5-year relative survival rate only 17%. Worse outcomes have been shown mismatch repair deficient (dMMR) subtype EC. Pembrolizumab (pembro), an anti-PD-1 antibody, showed compelling antitumor activity in previously treated, advanced MSI-H/dMMR EC phase 2 KEYNOTE-158...
<h3>Objective</h3> Olaparib plus bevacizumab maintenance therapy improves survival outcomes in women with newly diagnosed, advanced, high-grade ovarian cancer a deficiency homologous recombination. We report data from the first year of routine recombination testing National Health Service (NHS) England, Wales, and Northern Ireland between April 2021 2022. <h3>Methods</h3> The Myriad myChoice companion diagnostic was used to test DNA extracted formalin-fixed, paraffin-embedded tumor tissue...
Abstract Background The treatment landscape for advanced non-small cell lung cancer (aNSCLC) has evolved rapidly since immuno-oncology (IO) therapies were introduced. This study used recent data to assess real-world patterns and clinical outcomes in aNSCLC the United Kingdom. Methods Electronic prescribing records of treatment-naive patients starting first-line (1 L) between June 2016 March 2018 (follow-up until December 2018) Kingdom assessed retrospectively. Patient characteristics...
Over 50% of patients with ovarian cancer are diagnosed advanced disease (stage 3+) in Wales when treatment typically involves chemotherapy, combined cytoreductive surgery. Postoperative morbidity is common resulting prolonged hospital stays and delays returning to chemotherapy. Patients commonly have modifiable risk factors that can be targeted for improvement personalised prehabilitation. Multimodal prehabilitation has been shown a positive impact on perioperative outcomes length stay...
(Abstracted from Lancet 2024;404:1525–1535) Cervical cancer is the cause of 350,000 global deaths annually as 2022, and prevalence remains around 660,000 new cases a year. High-income countries have decreased incidence due to implementation screening vaccinations, but cervical most common in 23 leading death 36 countries.
Persistent hepatitis C virus (HCV) infection is a major cause of chronic liver disease, worldwide. With the development direct-acting antivirals, treatment chronically infected patients has become highly effective, although subset responds less well to therapy. Sofosbuvir common component current de novo or salvage combination therapies, that targets HCV NS5B polymerase. We use pre-treatment whole-genome sequences from 507 with subtype 3a and treated sofosbuvir containing regimens detect...
New directly acting antivirals (DAAs) provide very high cure rates in most patients infected by hepatitis C virus (HCV). However, some patient groups have been relatively harder to treat, including those with cirrhosis or HCV genotype 3. In the recent BOSON trial, 3, receiving a 16-week course of sofosbuvir and ribavirin had sustained virological response (SVR) rate around 50%. cirrhosis, interferon lambda 4 (IFNL4) CC was significantly associated SVR. This also lower interferon-stimulated...
<h3>Introduction/Background</h3> Locally advanced cervical cancer (LACC) is treated with chemoradiation (CRT). However, many patients relapse and die from metastatic disease. A feasibility study demonstrated a good response rate to 6 weeks of induction chemotherapy (IC) delivered before standard CRT. INTERLACE trial investigated whether this approach improves both progression free survival (PFS) overall (OS). <h3>Methodology</h3> Patients locally squamous, adeno or adenosquamous carcinoma...
<h3>Introduction/Background</h3> AtTEnd is a phase III randomized international academic trial showing the efficacy of atezolizumab in addition to standard carboplatin and paclitaxel (CP) patients (pts) with advanced/recurrent endometrial cancer. The potential for differences based on ethnicity unknown. <h3>Methodology</h3> In this post hoc analysis, we analyzed combination CP as maintenance vs alone comparing Asian cohort (AC) non-Asian (nAC). <h3>Results</h3> From Oct 2018 Jan 2022, 549...